Clinical Evaluation of Triphala Guggul as a Conservative Intervention for Karnasrava: A Randomized Trial
International Journal of Drug Delivery Technology · 05.05.2026 · 16 (24s)
DOI: 10.25258/ijddt.16.24s.70 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 05.05.2026. Verfasst von Dr. Sweta Nath und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Karnasrava, a condition classically described within Shalakya Tantra, clinically corresponds to pathological ear discharge or otorrhoea associated with disorders of the external or middle ear. This condition frequently induces significant physical discomfort, including pain, itching, and impaired hearing, leading to social embarrassment and a substantial recurrent treatment burden for affected patients. The present randomized comparative clinical study aimed to evaluate the therapeutic efficacy of Triphala Guggul in managing Karnasrava relative to Cefadroxil, a standard modern antibiotic utilized for infective ear discharge. A total of eighty patients, aged between 20 and 60 years, were enrolled from the outpatient and inpatient services of a Shalakya Tantra department. Participants were randomly divided into two equal groups of forty. The trial group was administered Triphala Guggul at 500 mg twice daily with lukewarm water, while the control group received Cefadroxil 500 mg twice daily, for eight days. Clinical assessments were performed on days 0, 2, 4, 6, and 8 based on four primary symptomatic parameters: Karnasrava (discharge), Karnashoola (pain), Karnakandu (itching), and Karnabadhirya (deafness). Statistical analysis was conducted using Wilcoxon signed-rank and Mann-Whitney tests. Within-group analysis revealed statistically significant improvements in both cohorts across all primary parameters. In the Triphala Guggul group, median discharge scores reduced from 4 to 1, whereas the control group achieved a reduction to 0. Although Triphala Guggul demonstrated meaningful therapeutic benefit, between-group comparisons significantly favored Cefadroxil for more rapid and complete symptomatic relief. Findings suggest that while Triphala Guggul is a safe, economical, and effective conservative option, Cefadroxil provides superior short-term symptom control. Most patients belonged to the 20–30-year age group. Triphala Guggul remains a viable alternative when affordability and tolerability are prioritized.
Zitieren
APA
Nath, D. S., Chavan, D. R. S., & Kamath, D. G. (2026). Clinical Evaluation of Triphala Guggul as a Conservative Intervention for Karnasrava: A Randomized Trial. International Journal of Drug Delivery Technology, 16(24s). https://doi.org/10.25258/ijddt.16.24s.70
Vancouver
Nath DS, Chavan DRS, Kamath DG. Clinical Evaluation of Triphala Guggul as a Conservative Intervention for Karnasrava: A Randomized Trial. International Journal of Drug Delivery Technology. 2026;16(24s). doi:10.25258/ijddt.16.24s.70
BibTeX
@article{Nath2026,
author = {Nath, Dr. Sweta and Chavan, Dr. Rohit Sambhaji and Kamath, Dr. Gayathri},
title = {Clinical Evaluation of Triphala Guggul as a Conservative Intervention for Karnasrava: A Randomized Trial},
journal = {International Journal of Drug Delivery Technology},
year = {2026},
volume = {16},
number = {24s},
doi = {10.25258/ijddt.16.24s.70}
}
EUVIMED